The biggest negative is that it is a completely new MOA. So we don't yet have proof of concept, which is a big hurdle to go on top of the standard drug development issues.
Pancreatic is indeed tough, but the safety and efficacy bars are correspondingly low, so net net it may be something of a wash.
Market Data 
Markets 
AI
